Today CMS announced the Part D Senior Savings Model, allowing Medicare Part D prescription drug plans to offer plan choices that provide a range of insulins to beneficiaries, at a maximum $35 copay per 30-day supply throughout the benefit year.
Today CMS announced the Part D Senior Savings Model, allowing Medicare Part D prescription drug plans to offer plan choices that provide a range of insulins to beneficiaries, at a maximum $35 copay per 30-day supply throughout the benefit year.
The model is voluntary and targeted to enhanced Part D plans, which offer more prescription drug coverage than basic benefit designs but have higher premiums. The Trump administration previously announced it was responsible for a 13.5% decline in the average monthly basic Part D premium since 2017 to the lowest level in 7 years.
Beneficiaries enrolled in a participating plan could “save an average of $446 in annual out-of-pocket costs for insulin, or over 66%, relative to their average cost-sharing for insulin today,” according to a press release. Currently, 1 in every 3 Medicare beneficiaries has diabetes and more than 3.3 million beneficiaries use one or more common forms of insulin.
CMS estimates the model will save the federal government $250 million over 5 years as the agency predicts pharmaceutical manufacturers will pay additional coverage gap discounts. The model includes coverage of formulary insulins, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins.
“Participating pharmaceutical manufacturers will pay the 70% discount in the coverage gap for the insulins that are included in the Model, but those manufacturer discount payments would now be calculated before the application of supplemental benefits under the Model,” the center stated.
To encourage Part D sponsor participation, CMS will also provide the option of risk corridor protection for calendar years 2021 and 2022 for plan benefit packages (PBPs) that “have higher enrollment than average from insulin-dependent diabetic patients, when the PBP meets qualifying criteria.”
“The Part D Senior Savings Model provides an innovative market-driven approach that removes barriers to lower insulin costs. We call on health insurance plans and prescription drug manufacturers to take action and provide relief for America’s seniors who take insulin,” said CMS administrator Seema Verma. “President Trump is delivering on his promise to lower the cost of prescription drugs for seniors.”
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More